| A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses RJ Svensson, RE Aarnoutse, AH Diacon, R Dawson, SH Gillespie, ... Clinical Pharmacology & Therapeutics 103 (4), 674-683, 2018 | 114 | 2018 |
| The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis EM Svensson, RJ Svensson, LHM Te Brake, MJ Boeree, N Heinrich, ... Clinical Infectious Diseases 67 (1), 34-41, 2018 | 98 | 2018 |
| Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations RJ Svensson, EM Svensson, RE Aarnoutse, AH Diacon, R Dawson, ... The Journal of infectious diseases 218 (6), 991-999, 2018 | 64 | 2018 |
| Application of the multistate tuberculosis pharmacometric model in patients with rifampicin‐treated pulmonary tuberculosis RJ Svensson, USH Simonsson CPT: pharmacometrics & systems pharmacology 5 (5), 264-273, 2016 | 37 | 2016 |
| Forecasting clinical dose–response from preclinical studies in tuberculosis research: translational predictions with rifampicin SG Wicha, O Clewe, RJ Svensson, SH Gillespie, Y Hu, ARM Coates, ... Clinical Pharmacology & Therapeutics 104 (6), 1208-1218, 2018 | 27 | 2018 |
| Individualised dosing algorithm and personalised treatment of high‐dose rifampicin for tuberculosis RJ Svensson, K Niward, L Davies Forsman, J Bruchfeld, J Paues, ... British journal of clinical pharmacology 85 (10), 2341-2350, 2019 | 20 | 2019 |
| Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods RJ Svensson, SH Gillespie, USH Simonsson Journal of Antimicrobial Chemotherapy 72 (8), 2311-2319, 2017 | 16 | 2017 |
| Drug effect of clofazimine on persisters explains an unexpected increase in bacterial load in patients A Faraj, RJ Svensson, AH Diacon, USH Simonsson Antimicrobial Agents and Chemotherapy 64 (5), 10.1128/aac. 01905-19, 2020 | 15 | 2020 |
| Rifampicin can be given as flat-dosing instead of weight-band dosing BO Susanto, RJ Svensson, EM Svensson, R Aarnoutse, MJ Boeree, ... Clinical Infectious Diseases 71 (12), 3055-3060, 2020 | 14 | 2020 |
| Improving treatment outcome assessment in a mouse tuberculosis model BC Mourik, RJ Svensson, GJ de Knegt, HI Bax, A Verbon, ... Scientific Reports 8 (1), 5714, 2018 | 12 | 2018 |
| Efficient and relevant stepwise covariate model building for pharmacometrics RJ Svensson, EN Jonsson CPT: pharmacometrics & systems pharmacology 11 (9), 1210-1222, 2022 | 9 | 2022 |
| Model-based relationship between the molecular bacterial load assay and time to positivity in liquid culture RJ Svensson, W Sabiiti, GS Kibiki, NE Ntinginya, N Bhatt, G Davies, ... Antimicrobial Agents and Chemotherapy 63 (10), 10.1128/aac. 00652-19, 2019 | 7 | 2019 |
| Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and … RJ Svensson, J Ribbing, N Kotani, M Dolton, S Vadhavkar, D Cheung, ... CPT: Pharmacometrics & Systems Pharmacology 10 (10), 1221-1235, 2021 | 6 | 2021 |
| Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions A Faraj, O Clewe, RJ Svensson, GV Mukamolova, MR Barer, ... Scientific Reports 10 (1), 15537, 2020 | 5 | 2020 |
| Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma N Kotani, M Dolton, RJ Svensson, J Ribbing, LE Friberg, S Vadhavkar, ... The Journal of Clinical Pharmacology 62 (7), 905-917, 2022 | 4 | 2022 |
| Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development R Ayoun Alsoud, RJ Svensson, EM Svensson, SH Gillespie, MJ Boeree, ... Frontiers in Pharmacology 14, 1067295, 2023 | 2 | 2023 |
| Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and … RJ Svensson, QX Ooi, LE Friberg, N Maharaj, PK Reddy, L López‐Lázaro, ... CPT: Pharmacometrics & Systems Pharmacology 12 (2), 154-167, 2023 | 2 | 2023 |
| Pharmacometric Models to Improve the Treatment and Development of Drugs against Tuberculosis RJ Svensson Acta Universitatis Upsaliensis, 2019 | | 2019 |
